Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Phase II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia (IND #77,021) CINCH 5306

ABSTRACT: Phase II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia (IND #77,021) CINCH 5306

PROVIDER: PRJNA377373 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Therapeutic Trial of Potassium and Acetazolamide in Andersen-Tawil Syndrome CINCH 5305

Project description:Therapeutic Trial of Potassium and Acetazolamide in Andersen-Tawil Syndrome CINCH 5305

| PRJNA377377 | ENA

Homo sapiens

Project description:Phase II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia (IND #77,021) CINCH 5306

| PRJNA377374 | ENA

Comparison of IND induced vs. mock treated seedlings: Transcriptome profiling upon induction of the transcription factor IND

Project description:rs10-03_ind - comparison of ind induced vs mock treated seedlings - Identification of miRNAs regulated by IND - Transgenic seeds containing an IND transgene under the control of a dexamethasone inducible promoter were germinated and grown in liquid Murashige/Skoog medium under a 16h light/8h darkness light regime. After seven days of growth, seedlings were either mock-treated or treated with 10 micromolar dexamethasone for 24 hours.

2011-05-12 | GSE28898 | GEO

Comparison of IND induced vs. mock treated seedlings: Transcriptome profiling upon induction of the transcription factor IND

2011-05-12 | E-GEOD-28898 | biostudies-arrayexpress

Expression data from wild and ind-6 mutant Arabidopsis silique during three development stages of fruit dehiscence

Project description:Fruit dehiscence is an essential developmental process of some economic crops that impacts dramatically on crop yields and involves altered regulation of thousands of genes, ind-6 gene is a transcription factor play important role during fruit dehiscence. Gene expression were examined in wild-type and ind-6 mutants at three development stages of fruit dehiscence to explore the molecular mechanism of ind-6 in fruit dehiscence. We used microarrays to examine changes in gene expression during fruit dehiscence and identified distinct classes of up- and down-regulated genes in wild-type and ind-6 mutant genotypes.

2015-12-28 | GSE66672 | GEO

Transcriptome analysis of genes regulated by INDEHISCENT (IND) transcription factor under the control of the 35S promoter after treatment with auxin

Project description:IND is a regulator of fruit development in Arabidopsis thaliana. To identify genes regulated by IND we performed array based transcriptome analysis of Dexamethasone (DEX) inducible IND transgenic seedlings. One week old 35S::IND:GR seedlings were treated with DMSO, Auxin, DEX and Auxin plus DEX for 6 h. Three biological independent experiments were performed.

2017-07-05 | E-MTAB-3812 | biostudies-arrayexpress

Trial

Project description:Trial Trial

| PRJEB7892 | ENA

Hydra vulgaris strain:Ind-Pune

Project description:Hydra vulgaris strain:Ind-Pune Epigenomics

| PRJNA532677 | ENA

Dystrophic single myofibers vs control single myofibers

Project description:MicroRNA-expression profile of dystrophic single fibres vs wild type single fibers isolated from different muscle of mdx and c57bl mice. Myofibers were isolated from different muscle type (tibialis, diaphragm and quadriceps of gender- (male) and age- (3 month old and half) matched wt and dystrophic mice). 9 total samples per animal model, 3 replicates per muscle type sample

2012-12-21 | E-GEOD-21219 | biostudies-arrayexpress

Mexiletine in Non-Dystrophic Myotonia

Project description:Non-dystrophic myotonias are a group of rare muscle disorders caused by abnormalities in different muscle cell membrane proteins. Patients experience delayed muscle relaxation that causes impaired physical activity, stiffness, and pain. Mexiletine has been shown to be beneficial for symptoms of myotonia in case reports of patients with non-dystrophic myotonia, however, current management of these patients primarily depends on individual practitioners' preference. This study is a placebo-controlled, double-blind, cross-over treatment trial using mexiletine in non-dystrophic myotonias. The results, if positive, will permit the identification of mexiletine as an effective therapy for myotonia, making it a first-line therapy for patients with non-dystrophic myotonia. The specific aim of this proposal is to perform a randomized, double-blind, placebo-controlled cross-over study to assess whether mexiletine improves both quantitative and qualitative measures of myotonia in patients with non-dystrophic myotonia. Given the rarity of non-dystrophic myotonia, large randomized controlled treatment trials in these disorders have not been feasible in the past. Primary Outcome Measure: Patient-assessed symptom: stiffness as measured by an Interactive Voice Response Diary (IVR). Secondary Outcome Measures: a) patient-assessed pain, weakness, and fatigue as measured by IVR; b) clinical myotonia assessment; c) quality of life as measured by INQoL, SF36; d) a quantitative measure of grip myotonia; e) measurement of CMAP after short and long exercise; f) grading of myotonia on needle EMG.

| phs001311 | dbGaP

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data